The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells

Journal of Cancer Research and Clinical Oncology

Volumn 131, Issue 6, 2005, Pages 385-394

  Ocker, Matthias ^a   Alajati, Abdullah ^a   Ganslmayer, Marion ^a   Zopf, Steffen ^a   Lüders, Mike ^a   Neureiter, Daniel ^a   Hahn, Eckhart G ^a   Schuppan, Detlef ^a   Herold, Christoph ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

5FU; HDAC; Hepatocellular carcinoma; Irinotecan; SAHA

Indexed keywords

CASPASE 8; FLUOROURACIL; HISTONE DEACETYLASE INHIBITOR; IRINOTECAN; PROTEIN BCL 2; VORINOSTAT;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL STRAIN HEPG2; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVATION; FIBROBLAST; GROWTH INHIBITION; HEPATOMA CELL; HUMAN; HUMAN CELL; INCUBATION TIME; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CAMPTOTHECIN; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CASPASE 8; CASPASES; DOWN-REGULATION; DRUG SYNERGISM; ENZYME ACTIVATION; ENZYME INHIBITORS; FIBROBLASTS; FLUOROURACIL; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; LIVER NEOPLASMS; MEMBRANE POTENTIALS; MITOCHONDRIA; PROTO-ONCOGENE PROTEINS C-BCL-2; SKIN; TUMOR CELLS, CULTURED;

EID: 18744408483     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-004-0664-6     Document Type: Article

References (33)

1. Benson AB III, Mitchel E, Abramson N, Klencke B, Ritch P, Burnham JP, McGuirt C, Bonny T, Levin J, Hohneker J (2002) Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. Ann Oncol 13:576-581
2. Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA, Richon VM (2000) Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60:5165-5170
3. Butler LM, Zhou X, Xu WS, Scher HI, Rifkind RA, Marks PA, Richon VM (2002) The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci U S A 99:11700-11705
4. Cance WG, Stewart AK, Menck HR (2000) The national cancer data base report on treatment patterns for hepatocellular carcinoma. Cancer 88:912-920
5. Cao S, Rustum YM (2000) Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose. Cancer Res 60:3717-3721
6. Diasia RB, Harris BE (1989) Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16:215-237
7. Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385-427
8. Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20:6969-6978
9. Guichard S, Cussac D, Hennebelle I, Bugat R, Canal P (1997) Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo. Int J Cancer 73:729-734
10. Guichard S, Hennebelle I, Bugat R, Canal P (1998) Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line. Biochem Pharmacol 55:667-676
11. Gupta E, Wang X, Ramirez J, Ratain MJ (1997) Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital. Cancer Chemother Pharmacol 39:440-444
12. Henderson C, Mizzau M, Paroni G, Maestro R, Schneider C, Brancolini C (2003) Role of caspases, bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J Biol Chem 278:12579-12589
13. Herold C, Ganslmayer M, Ocker M, Hermann M, Geerts A, Hahn EG, Schuppan D (2002) The histone-deacetylase inhibitor trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J Hepatol 36:233-240
14. Johnstone RW (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Cancer 1:287-299
15. Lavelle D, Chen YH, Hankewych M, DeSimone J (2001) Histone deacetylase inhibitors increase p21waf1 and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression. Am J Hematol 68:170-178
16. Leers MP, Kolgen W, Bjorklund V, Bergman T, Tribbick G, Persson B, Bjorklund P, Ramaekers FC, Bjorklund B, Nap M, Jornvall H, Schutte B (1999) Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 187:567-572
17. Legrand O, Perrot JY, Simonin G, Baudard M, Marie JP (2001) JC-1: a very sensitive fluorescent probe to test Pgp activity in adult myeloid leukemia. Blood 97:502-508
18. Lin DY, Lin SM, Liaw YF (1997) Non-surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 12:S319-S328
19. Longley DB, Harkin DP, Johnston PG (2003) 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3:330-338
20. Mancini M, Anderson BO, Caldwell E, Sedghinasab M, Paty PB, Hockenbery DM (1997) Mitochondrial proliferation and paradoxical membrane depolarization during terminal differentiation and apoptosis in a human colon carcinoma cell line. J Cell Biol 138:449-469
21. Marks PA, Richon VM, Rifkind RA (2000) Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92:1210-1216
22. Mathurin P, Rixe O, Carbonell N, Bernard B, Cluzel P, Bellin MF, Khayat D, Opolon P, Poynard T (1998) Overview of medical treatments in unresectable hepatocellular carcinoma - an impossible meta-analysis? Aliment Pharmacol Ther 12:111-126
23. Okuda K (2000) Hepatocellular carcinoma. J Hepatol 32 [Suppl 1]:225-237
24. O'Reilly EM, Stuart KE, Sanz-Altamira PM, Schwartz GK, Steger CM, Raeburn L, Kemeny NE, Kelsen DP, Saltz LB (2001) A phase II study of irinotecan in patients with advanced hepatocellular carcinoma. Cancer 91:101-105
25. Pavillard V, Formento P, Rostagno P, Formento JL, Fischel JL, Francoual M, Etienne MC, Milano G (1998) Combination of irinotecan (CPT11) and 5-fluorouracil with an analysis of cellular determinants of drug activity. Biochem Pharmacol 56:1315-1322
26. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276:36734-36741
27. Richon VM, Sandhoff TW, Rifkind RA, Marks PA (2000) Histone deacetylase inhibitor selectively induces p21waf1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 97:10014-10019
28. Rothenberg ML (2001) Irinotecan (CPT-11): recent developments and future directions - colorectal cancer and beyond. Oncologist 6:66-80
29. Ruefli AA, Bernhard D, Tainton KM, Kofler R, Smyth MJ, Johnstone RW (2002) Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in p-glycoprotein-expressing cells. Int J Cancer 99:292-298
30. Sambucetti LC, Fischer DD, Zabludoff S, Kwon PO, Chamberlin H, Trogani N, Xu H, Cohen D (1999) Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J Biol Chem 274:34930-34947
31. Smiley ST, Reers M, Mottola-Hartshorn C, Lin M, Chen A, Smith TW, Steele GD Jr, Chen LB (1991) Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proc Natl Acad Sci U S A 88:3671-3675
32. Xu Y, Villalona-Calero MA (2002) Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol 13:1841-1851
33. Yu AS, Keeffe EB (2003) Management of hepatocellular carcinoma. Rev Gastroenterol Disord 3:8-24